Astrazeneca Plc ADR
(NQ:
AZN
)
77.94
+0.19 (+0.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,168,275
Open
78.15
Bid (Size)
77.00 (1)
Ask (Size)
78.25 (3)
Prev. Close
77.75
Today's Range
77.86 - 78.59
52wk Range
60.47 - 80.86
Shares Outstanding
N/A
Dividend Yield
1.19%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
July 10, 2024
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside.
Via
InvestorPlace
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
July 05, 2024
New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying after the election.
Via
Benzinga
Topics
ETFs
Performance
YTD
+13.95%
+13.95%
1 Month
-2.83%
-2.83%
3 Month
+14.43%
+14.43%
6 Month
+12.03%
+12.03%
1 Year
+20.17%
+20.17%
More News
Read More
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
Via
Investor's Business Daily
3 Set-It-and-Forget-It Stocks for Lasting Financial Security
July 02, 2024
Via
InvestorPlace
AstraZeneca's COVID-19 Prevention Drug For Patients With Weak Immune Systems - European Medicines Agency Accepts Marketing Application Under Accelerated Assessment
July 01, 2024
Via
Benzinga
Exposures
COVID-19
7 Biotech Stocks to Boost Your Portfolio to Peak Health
June 26, 2024
Via
InvestorPlace
China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients
June 26, 2024
Via
Benzinga
AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study
June 25, 2024
Via
Benzinga
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
June 25, 2024
From
AstraZeneca
Via
Business Wire
3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains
June 24, 2024
Via
InvestorPlace
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
June 24, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
June 24, 2024
Via
InvestorPlace
The 3 Healthiest Healthcare Stocks to Buy for a Huge Dose of Profits
June 23, 2024
Via
InvestorPlace
3 No-Brainer Stocks to Buy for Under $100 Right Now
June 22, 2024
Via
The Motley Fool
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
Via
Benzinga
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
June 20, 2024
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Eli Lilly's Stock Surge Driven by GLP-1 Demand
June 20, 2024
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
June 18, 2024
Via
Benzinga
Exposures
COVID-19
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial
June 18, 2024
Via
Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
June 17, 2024
Via
Benzinga
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
June 17, 2024
From
AstraZeneca
Via
Business Wire
FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer
June 17, 2024
Via
Benzinga
Exposures
Product Safety
3 Best Stocks to Buy From the Fantastic 5
June 17, 2024
Via
InvestorPlace
AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer
June 17, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.